Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada

Summary

Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada is a doctoral thesis^[1].

Key Facts

• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada authored issues arising from value assessment processes in the European Union, the United Kingdom and Canada — author (P50): Anna-Maria Fontrier^[2].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's instance of is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — instance of (P31): doctoral thesis^[3].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's DOI is recorded as 10.21953/LSE.00004621^[4].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's language of work or name is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — language of work or name (P407): English^[5].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's publication date is recorded as +2023-00-00T00:00:00Z^[6].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's work available at URL is recorded as https://researchonline.lse.ac.uk/id/eprint/135489/^[7].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's number of pages is recorded as {'unit': '1', 'amount': '+343'}^[8].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's title is recorded as Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada^[9].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's thesis submitted to is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — thesis submitted to (P4101): London School of Economics and Political Science^[10].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's on focus list of Wikimedia project is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — on focus list of Wikimedia project (P5008): LSEThesisProject^[11].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's copyright status is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — copyright status (P6216): copyrighted^[12].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's online access status is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — online access status (P6954): open access^[13].
• Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's access restriction status is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — access restriction status (P7228): open access^[14].

Body

Designation and Status

Entry to market of new medicines and medicines treating rare diseases: issues arising from value assessment processes in the European Union, the United Kingdom and Canada's instance of is recorded as issues arising from value assessment processes in the European Union, the United Kingdom and Canada — instance of (P31): doctoral thesis^[3].